What lies behind serum urate concentration? Insights from genetic and genomic studies

Genome Medicine

Volumn 1, Issue 12, 2009, Pages

  Ichida, Kimiyoshi ^a  

^a TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; GLUCOKINASE; GLUCOSE TRANSPORTER; LEUCINE RICH REPEAT CONTAINING PROTEIN 16A; MONOCARBOXYLATE TRANSPORTER; MONOCARBOXYLATE TRANSPORTER 9; MULTIDRUG RESISTANCE PROTEIN 4; ORGANIC ANION TRANSPORTER; ORGANIC ANION TRANSPORTER 4; PDZ PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; REGULATOR PROTEIN; SODIUM PHOSPHATE COTRANSPORTER 1; SODIUM PHOSPHATE COTRANSPORTER 11; SODIUM PHOSPHATE COTRANSPORTER 3; SODIUM PHOSPHATE COTRANSPORTER 4; UNCLASSIFIED DRUG; URATE;

APICAL MEMBRANE; BASOLATERAL MEMBRANE; GENE EXPRESSION; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC CODE; HUMAN; HYPERURICEMIA; INSULIN RESISTANCE; KIDNEY; NONHUMAN; OBESITY; PDZ DOMAIN; PRIORITY JOURNAL; PURINE METABOLISM; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; URIC ACID BLOOD LEVEL; URIC ACID URINE LEVEL;

EID: 77955657665     PISSN: None     EISSN: 1756994X     Source Type: Journal    
DOI: 10.1186/gm118     Document Type: Review

References (83)

1. Edwards NL. The role of hyperuricemia in vascular disorders. Curr Opin Rheumatol 2009, 21:132-137. 10.1097/BOR.0b013e3283257b96, 19339923.
2. Schachter M. Uric acid and hypertension. Curr Pharm Des 2005, 11:4139-4143. 10.2174/138161205774913246, 16375735.
3. Ichida K, Hosoyamada M, Hisatome I, Enomoto A, Hikita M, Endou H, Hosoya T. Clinical and molecular analysis of patients with renal hypouricemia in Japan-influence of URAT1 gene on urinary urate excretion. J Am Soc Nephrol 2004, 15:164-173. 10.1097/01.ASN.0000105320.04395.D0, 14694169.
4. Facchini F, Chen YD, Hollenbeck CB, Reaven GM. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA 1991, 266:3008-3011. 10.1001/jama.266.21.3008, 1820474.
5. Johnson RJ, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanabe S, Tuttle KR, Rodriguez-Iturbe B, Herrera-Acosta J, Mazzali M. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease?. Hypertension 2003, 41:1183-1190. 10.1161/01.HYP.0000069700.62727.C5, 12707287.
6. Kanellis J, Kang DH. Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. Semin Nephrol 2005, 25:39-42. 10.1016/j.semnephrol.2004.09.007, 15660333.
7. OMIM: Lesch-Nyhan Syndrome. (accessed 11 November 2009).., http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=300322
8. OMIM: Hyperuricemic nephropathy, familial juvenile 1; HNFJ1. (accessed 11 November 2009).., http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=162000
9. OMIM: Molybdenum Cofactor Deficiency. (accessed 11 November 2009).., http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=252150
10. Ichida K, Amaya Y, Kamatani N, Nishino T, Hosoya T, Sakai O. Identification of two mutations in human xanthine dehydrogenase gene responsible for classical type I xanthinuria. J Clin Invest 1997, 99:2391-2397. 10.1172/JCI119421, 508078, 9153281.
11. Ichida K, Matsumura T, Sakuma R, Hosoya T, Nishino T. Mutation of human molybdenum cofactor sulfurase gene is responsible for classical xanthinuria type II. Biochem Biophys Res Commun 2001, 282:1194-1200. 10.1006/bbrc.2001.4719, 11302742.
12. OMIM: Xanthinuria type I. (accessed 11 November 2009).., http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=278300
13. OMIM: Xanthinuria type II. (accessed 11 November 2009).., http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=603592
14. OMIM: Hypouricemuia, renal, 1, RHUC1. (accessed 11 November 2009).., http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=220150
15. OMIM: Hypouricemuia, renal, 2, RHUC2. (accessed 11 Nov ember 2009).., http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=612076
16. Hart TC, Gorry MC, Hart PS, Woodard AS, Shihabi Z, Sandhu J, Shirts B, Xu L, Zhu H, Barmada MM, Bleyer AJ. Mutations of the UMOD gene are responsible for medullary cystic kidney disease 2 and familial juvenile hyperuricaemic nephropathy. J Med Genet 2002, 39:882-892. 10.1136/jmg.39.12.882, 1757206, 12471200.
17. Rampoldi L, Caridi G, Santon D, Boaretto F, Bernascone I, Lamorte G, Tardanico R, Dagnino M, Colussi G, Scolari F, Ghiggeri GM, Amoroso A, Casari G. Allelism of MCKD, FJHN and GCKD caused by impairment of uromodulin export dynamics. Hum Mol Genet 2003, 12:3369-3384. 10.1093/hmg/ddg353, 14570709.
18. Enomoto A, Kimura H, Chairoungdua A, Shigeta Y, Jutabha P, Cha SH, Hosoyamada M, Takeda M, Sekine T, Igarashi T, Matsuo H, Kikuchi Y, Oda T, Ichida K, Hosoya T, Shimokata K, Niwa T, Kanai Y, Endou H. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 2002, 417:447-452.
19. Guggino SE, Aronson PS. Paradoxical effects of pyrazinoate and nicotinate on urate transport in dog renal microvillus membranes. J Clin Invest 1985, 76:543-547. 10.1172/JCI112004, 423858, 4031062.
20. Roch-Ramel F, Guisan B, Diezi J. Effects of uricosuric and antiuricosuric agents on urate transport in human brush-border membrane vesicles. J Pharmacol Exp Ther 1997, 280:839-845.
21. Li S, Sanna S, Maschio A, Busonero F, Usala G, Mulas A, Lai S, Dei M, Orru M, Albai G, Bandinelli S, Schlessinger D, Lakatta E, Scuteri A, Najjar SS, Guralnik J, Naitza S, Crisponi L, Cao A, Abecasis G, Ferrucci L, Uda M, Chen WM, Nagaraja R. The GLUT9 gene is associated with serum uric acid levels in Sardinia and Chianti cohorts. PLoS Genet 2007, 3:e194. 10.1371/journal.pgen.0030194, 2065883,2065883, 17997608.
22. Wallace C, Newhouse SJ, Braund P, Zhang F, Tobin M, Falchi M, Ahmadi K, Dobson RJ, Marcano AC, Hajat C, Burton P, Deloukas P, Brown M, Connell JM, Dominiczak A, Lathrop GM, Webster J, Farrall M, Spector T, Samani NJ, Caulfield MJ, Munroe PB. Genome-wide association study identifies genes for biomarkers of cardiovascular disease: serum urate and dyslipidemia. Am J Hum Genet 2008, 82:139-149. 10.1016/j.ajhg.2007.11.001, 2253977, 18179892.
23. Dehghan A, Kottgen A, Yang Q, Hwang SJ, Kao WL, Rivadeneira F, Boerwinkle E, Levy D, Hofman A, Astor BC, Benjamin EJ, van Duijn CM, Witteman JC, Coresh J, Fox CS. Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. Lancet 2008, 372:1953-1961. 10.1016/S0140-6736(08)61343-4, 2803340, 18834626.
24. Doring A, Gieger C, Mehta D, Gohlke H, Prokisch H, Coassin S, Fischer G, Henke K, Klopp N, Kronenberg F, Paulweber B, Pfeufer A, Rosskopf D, Volzke H, Illig T, Meitinger T, Wichmann HE, Meisinger C. SLC2A9 influences uric acid concentrations with pronounced sex-specific effects. Nat Genet 2008, 40:430-436. 10.1038/ng.107, 18327256.
25. McArdle PF, Parsa A, Chang YP, Weir MR, O'Connell JR, Mitchell BD, Shuldiner AR. Association of a common nonsynonymous variant in GLUT9 with serum uric acid levels in old order amish. Arthritis Rheum 2008, 58:2874-2881. 10.1002/art.23752, 2779583, 18759275.
26. Vitart V, Rudan I, Hayward C, Gray NK, Floyd J, Palmer CN, Knott SA, Kolcic I, Polasek O, Graessler J, Wilson JF, Marinaki A, Riches PL, Shu X, Janicijevic B, Smolej-Narancic N, Gorgoni B, Morgan J, Campbell S, Biloglav Z, Barac-Lauc L, Pericic M, Klaric IM, Zgaga L, Skaric-Juric T, Wild SH, Richardson WA, Hohenstein P, Kimber CH, Tenesa A, et al. SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nat Genet 2008, 40:437-442. 10.1038/ng.106, 18327257.
27. Kolz M, Johnson T, Sanna S, Teumer A, Vitart V, Perola M, Mangino M, Albrecht E, Wallace C, Farrall M, Johansson A, Nyholt DR, Aulchenko Y, Beckmann JS, Bergmann S, Bochud M, Brown M, Campbell H, Connell J, Dominiczak A, Homuth G, Lamina C, McCarthy MI, Meitinger T, Mooser V, Munroe P, Nauck M, Peden J, Prokisch H, Salo P, et al. Meta-analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations. PLoS Genet 2009, 5:e1000504. 10.1371/journal.pgen.1000504, 2683940, 19503597.
28. Zemunik T, Boban M, Lauc G, Jankovic S, Rotim K, Vatavuk Z, Bencic G, Dogas Z, Boraska V, Torlak V, Susac J, Zobic I, Rudan D, Pulanic D, Modun D, Mudnic I, Gunjaca G, Budimir D, Hayward C, Vitart V, Wright AF, Campbell H, Rudan I. Genome-wide association study of biochemical traits in Korcula Island, Croatia. Croat Med J 2009, 50:23-33. 10.3325/cmj.2009.50.23, 2657564, 19260141.
29. Iwai N, Mino Y, Hosoyamada M, Tago N, Kokubo Y, Endou H. A high prevalence of renal hypouricemia caused by inactive SLC22A12 in Japanese. Kidney Int 2004, 66:935-944. 10.1111/j.1523-1755.2004.00839.x, 15327384.
30. Taniguchi A, Urano W, Yamanaka M, Yamanaka H, Hosoyamada M, Endou H, Kamatani N. A common mutation in an organic anion transporter gene, SLC22A12, is a suppressing factor for the development of gout. Arthritis Rheum 2005, 52:2576-2577. 10.1002/art.21242, 16059895.
31. Ichida K, Hosoyamada M, Kamatani N, Kamitsuji S, Hisatome I, Shibasaki T, Hosoya T. Age and origin of the G774A mutation in SLC22A12 causing renal hypouricemia in Japanese. Clin Genet 2008, 74:243-251. 10.1111/j.1399-0004.2008.01021.x, 18492088.
32. Phay JE, Hussain HB, Moley JF. Cloning and expression analysis of a novel member of the facilitative glucose transporter family, SLC2A9 (GLUT9). Genomics 2000, 66:217-220. 10.1006/geno.2000.6195, 10860667.
33. Stark K, Reinhard W, Neureuther K, Wiedmann S, Sedlacek K, Baessler A, Fischer M, Weber S, Kaess B, Erdmann J, Schunkert H, Hengstenberg C. Association of common polymorphisms in GLUT9 gene with gout but not with coronary artery disease in a large case-control study. PLoS One 2008, 3:e1948. 10.1371/journal.pone.0001948, 2275796, 18398472.
34. Augustin R, Carayannopoulos MO, Dowd LO, Phay JE, Moley JF, Moley KH. Identification and characterization of human glucose transporter-like protein-9 (GLUT9): alternative splicing alters trafficking. J Biol Chem 2004, 279:16229-16236. 10.1074/jbc.M312226200, 14739288.
35. Anzai N, Ichida K, Jutabha P, Kimura T, Babu E, Jin CJ, Srivastava S, Kitamura K, Hisatome I, Endou H, Sakurai H. Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans. J Biol Chem 2008, 283:26834-26838. 10.1074/jbc.C800156200, 18701466.
36. Caulfield MJ, Munroe PB, O'Neill D, Witkowska K, Charchar FJ, Doblado M, Evans S, Eyheramendy S, Onipinla A, Howard P, Shaw-Hawkins S, Dobson RJ, Wallace C, Newhouse SJ, Brown M, Connell JM, Dominiczak A, Farrall M, Lathrop GM, Samani NJ, Kumari M, Marmot M, Brunner E, Chambers J, Elliott P, Kooner J, Laan M, Org E, Veldre G, Viigimaa M, et al. SLC2A9 is a high-capacity urate transporter in humans. PLoS Med 2008, 5:e197. 10.1371/journal.pmed.0050197, 2561076,2561076, 18842065.
37. Matsuo H, Chiba T, Nagamori S, Nakayama A, Domoto H, Phetdee K, Wiriyasermkul P, Kikuchi Y, Oda T, Nishiyama J, Nakamura T, Morimoto Y, Kamakura K, Sakurai Y, Nonoyama S, Kanai Y, Shinomiya N. Mutations in glucose transporter 9 gene SLC2A9 cause renal hypouricemia. Am J Hum Genet 2008, 83:744-751. 10.1016/j.ajhg.2008.11.001, 2668068, 19026395.
38. Preitner F, Bonny O, Laverriere A, Rotman S, Firsov D, Da Costa A, Metref S, Thorens B. Glut9 is a major regulator of urate homeostasis and its genetic inactivation induces hyperuricosuria and urate nephropathy. Proc Natl Acad Sci USA 2009, 106:15501-15506. 10.1073/pnas.0904411106, 2741280, 19706426.
39. Allikmets R, Schriml LM, Hutchinson A, Romano-Spica V, Dean M. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res 1998, 58:5337-5339.
40. Mao Q, Unadkat JD. Role of the breast cancer resistance protein (ABCG2) in drug transport. AAPS J 2005, 7:E118-133. 10.1208/aapsj070112, 2751502, 16146333.
41. Huls M, Brown CD, Windass AS, Sayer R, Heuvel JJ, Heemskerk S, Russel FG, Masereeuw R. The breast cancer resistance protein transporter ABCG2 is expressed in the human kidney proximal tubule apical membrane. Kidney Int 2008, 73:220-225. 10.1038/sj.ki.5002645, 17978814.
42. Jonker JW, Buitelaar M, Wagenaar E, Valk MA, Scheffer GL, Scheper RJ, Plosch T, Kuipers F, Elferink RP, Rosing H, Beijnen JH, Schinkel AH. The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci USA 2002, 99:15649-15654. 10.1073/pnas.202607599, 137771, 12429862.
43. Woodward OM, Kottgen A, Coresh J, Boerwinkle E, Guggino WB, Kottgen M. Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout. Proc Natl Acad Sci USA 2009, 106:10338-10342. 10.1073/pnas.0901249106, 2700910, 19506252.
44. Matsuo H, Takada T, Ichida K, Nakamura T, Nakayama A, Ikebuchi Y, Ito K, Kusanagi Y, Chiba T, Tadokoro S, Takada Y, Oikawa Y, Inoue H, Suzuki K, Okada R, Nishiyama J, Domoto H, Watanabe S, Fujita M, Morimoto Y, Naito M, Nishio K, Hishida A, Wakai K, Asai Y, Niwa K, Kamakura K, Nonoyama S, Sakurai Y, Hosoya T, et al. Common defects of ABCG2, a high-capacity urate exporter, cause gout: a function-based genetic analysis in a Japanese population. Science Translational Medicine 2009, 1:5ra11. 10.1126/scitranslmed.3000237, 20368174.
45. Cha SH, Sekine T, Kusuhara H, Yu E, Kim JY, Kim DK, Sugiyama Y, Kanai Y, Endou H. Molecular cloning and characterization of multispecific organic anion transporter 4 expressed in the placenta. J Biol Chem 2000, 275:4507-4512. 10.1074/jbc.275.6.4507, 10660625.
46. Ekaratanawong S, Anzai N, Jutabha P, Miyazaki H, Noshiro R, Takeda M, Kanai Y, Sophasan S, Endou H. Human organic anion transporter 4 is a renal apical organic anion/dicarboxylate exchanger in the proximal tubules. J Pharmacol Sci 2004, 94:297-304. 10.1254/jphs.94.297, 15037815.
47. Kimura H, Takeda M, Narikawa S, Enomoto A, Ichida K, Endou H. Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. J Pharmacol Exp Ther 2002, 301:293-298. 10.1124/jpet.301.1.293, 11907186.
48. Hagos Y, Stein D, Ugele B, Burckhardt G, Bahn A. Human renal organic anion transporter 4 operates as an asymmetric urate transporter. J Am Soc Nephrol 2007, 18:430-439. 10.1681/ASN.2006040415, 17229912.
49. Enomoto A, Takeda M, Shimoda M, Narikawa S, Kobayashi Y, Yamamoto T, Sekine T, Cha SH, Niwa T, Endou H. Interaction of human organic anion transporters 2 and 4 with organic anion transport inhibitors. J Pharmacol Exp Ther 2002, 301:797-802. 10.1124/jpet.301.3.797, 12023506.
50. Hashimoto T, Narikawa S, Huang XL, Minematsu T, Usui T, Kamimura H, Endou H. Characterization of the renal tubular transport of zonampanel, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor antagonist, by human organic anion transporters. Drug Metab Dispos 2004, 32:1096-1102.
51. Chong SS, Kristjansson K, Zoghbi HY, Hughes MR. Molecular cloning of the cDNA encoding a human renal sodium phosphate transport protein and its assignment to chromosome 6p21.3-p23. Genomics 1993, 18:355-359. 10.1006/geno.1993.1476, 8288239.
52. Uchino H, Tamai I, Yamashita K, Minemoto Y, Sai Y, Yabuuchi H, Miyamoto K, Takeda E, Tsuji A. p-aminohippuric acid transport at renal apical membrane mediated by human inorganic phosphate transporter NPT1. Biochem Biophys Res Commun 2000, 270:254-259. 10.1006/bbrc.2000.2407, 10733936.
53. Urano W, Taniguchi A, Anzai N, Inoue E, Kanai Y, Yamanaka M, Kamatani N, Endou H, Yamanaka H. Sodium-dependent phosphate cotransporter type 1 (NPT1) sequence polymorphisms in male patients with gout. Ann Rheum Dis 2009,
54. Melis D, Havelaar AC, Verbeek E, Smit GP, Benedetti A, Mancini GM, Verheijen F. NPT4, a new microsomal phosphate transporter: mutation analysis in glycogen storage disease type Ic. J Inherit Metab Dis 2004, 27:725-733. 10.1023/B:BOLI.0000045755.89308.2f, 15505377.
55. Kocher O, Comella N, Tognazzi K, Brown LF. Identification and partial characterization of PDZK1: a novel protein containing PDZ interaction domains. Lab Invest 1998, 78:117-125.
56. Anzai N, Miyazaki H, Noshiro R, Khamdang S, Chairoungdua A, Shin HJ, Enomoto A, Sakamoto S, Hirata T, Tomita K, Kanai Y, Endou H. The multivalent PDZ domain-containing protein PDZK1 regulates transport activity of renal urate-anion exchanger URAT1 via its C terminus. J Biol Chem 2004, 279:45942-45950. 10.1074/jbc.M406724200, 15304510.
57. Miyazaki H, Anzai N, Ekaratanawong S, Sakata T, Shin HJ, Jutabha P, Hirata T, He X, Nonoguchi H, Tomita K, Kanai Y, Endou H. Modulation of renal apical organic anion transporter 4 function by two PDZ domain-containing proteins. J Am Soc Nephrol 2005, 16:3498-3506. 10.1681/ASN.2005030306, 16236806.
58. Jutabha P, Anzai N, Endou H, et al. Interaction of the multivalent PDZ damain protein PDZK1 with type 1 sodium-phosphate cotransporter (NPT1). J Am Soc Nephrol 2005, 16:350A.
59. Kahn AM. Indirect coupling between sodium and urate transport in the proximal tubule. Kidney Int 1989, 36:378-384. 10.1038/ki.1989.206, 2687564.
60. Roch-Ramel F, Guisan B, Schild L. Indirect coupling of urate and p-aminohippurate transport to sodium in human brush-border membrane vesicles. Am J Physiol 1996, 270:F61-68.
61. Gopal E, Fei YJ, Sugawara M, Miyauchi S, Zhuang L, Martin P, Smith SB, Prasad PD, Ganapathy V. Expression of slc5a8 in kidney and its role in Na(+)-coupled transport of lactate. J Biol Chem 2004, 279:44522-44532. 10.1074/jbc.M405365200, 15322102.
62. Anzai N, Kanai Y, Endou H. New insights into renal transport of urate. Curr Opin Rheumatol 2007, 19:151-157. 10.1097/BOR.0b013e328032781a, 17278930.
63. Mardones P, Pilon A, Bouly M, Duran D, Nishimoto T, Arai H, Kozarsky KF, Altayo M, Miquel JF, Luc G, Clavey V, Staels B, Rigotti A. Fibrates down-regulate hepatic scavenger receptor class B type I protein expression in mice. J Biol Chem 2003, 278:7884-7890. 10.1074/jbc.M211627200, 12511553.
64. Tachibana K, Anzai N, Ueda C, Katayama T, Yamasaki D, Kirino T, Takahashi R, Ishimoto K, Komori H, Tanaka T, Hamakubo T, Ueda Y, Arai H, Sakai J, Kodama T, Doi T. Regulation of the human PDZK1 expression by peroxisome proliferator-activated receptor alpha. FEBS Lett 2008, 582:3884-3888. 10.1016/j.febslet.2008.10.027, 18955051.
65. Halestrap AP, Price NT. The proton-linked monocarboxylate transporter (MCT) family: structure, function and regulation. Biochem J 1999, 343:281-299. 10.1042/0264-6021:3430281, 1220552, 10510291.
66. Wagner L, Oliyarnyk O, Gartner W, Nowotny P, Groeger M, Kaserer K, Waldhausl W, Pasternack MS. Cloning and expression of secretagogin, a novel neuroendocrine- and pancreatic islet of Langerhans-specific Ca2+-binding protein. J Biol Chem 2000, 275:24740-24751. 10.1074/jbc.M001974200, 10811645.
67. Farrelly D, Brown KS, Tieman A, Ren J, Lira SA, Hagan D, Gregg R, Mookhtiar KA, Hariharan N. Mice mutant for glucokinase regulatory protein exhibit decreased liver glucokinase: a sequestration mechanism in metabolic regulation. Proc Natl Acad Sci USA 1999, 96:14511-14516. 10.1073/pnas.96.25.14511, 24467, 10588736.
68. Shiota C, Coffey J, Grimsby J, Grippo JF, Magnuson MA. Nuclear import of hepatic glucokinase depends upon glucokinase regulatory protein, whereas export is due to a nuclear export signal sequence in glucokinase. J Biol Chem 1999, 274:37125-37130. 10.1074/jbc.274.52.37125, 10601273.
69. Saxena R, Voight BF, Lyssenko V, Burtt NP, de Bakker PI, Chen H, Roix JJ, Kathiresan S, Hirschhorn JN, Daly MJ, Hughes TE, Groop L, Altshuler D, Almgren P, Florez JC, Meyer J, Ardlie K, Bengtsson Bostrom K, Isomaa B, Lettre G, Lindblad U, Lyon HN, Melander O, Newton-Cheh C, Nilsson P, Orho-Melander M, Rastam L, Speliotes EK, Taskinen MR, Tuomi T, et al. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 2007, 316:1331-1336. 10.1126/science.1142358, 17463246.
70. Vaxillaire M, Cavalcanti-Proenca C, Dechaume A, Tichet J, Marre M, Balkau B, Froguel P. The common P446L polymorphism in GCKR inversely modulates fasting glucose and triglyceride levels and reduces type 2 diabetes risk in the DESIR prospective general French population. Diabetes 2008, 57:2253-2257. 10.2337/db07-1807, 2494697, 18556336.
71. Perez-Martinez P, Corella D, Shen J, Arnett DK, Yiannakouris N, Tai ES, Orho-Melander M, Tucker KL, Tsai M, Straka RJ, Province M, Kai CS, Perez-Jimenez F, Lai CQ, Lopez-Miranda J, Guillen M, Parnell LD, Borecki I, Kathiresan S, Ordovas JM. Association between glucokinase regulatory protein (GCKR) and apolipoprotein A5 (APOA5) gene polymorphisms and triacylglycerol concentrations in fasting, postprandial, and fenofibrate-treated states. Am J Clin Nutr 2009, 89:391-399. 10.3945/ajcn.2008.26363, 2647710, 19056598.
72. Quinones Galvan A, Natali A, Baldi S, Frascerra S, Sanna G, Ciociaro D, Ferrannini E. Effect of insulin on uric acid excretion in humans. Am J Physiol 1995, 268:E1-5.
73. Bakker SJ, Gans RO, ter Maaten JC, Teerlink T, Westerhoff HV, Heine RJ. The potential role of adenosine in the pathophysiology of the insulin resistance syndrome. Atherosclerosis 2001, 155:283-290. 10.1016/S0021-9150(00)00745-0, 11254897.
74. Hosoya T, Ueda T, Kamatani N, Nakajima H, Hisatome I, Fujimori S, Yamanaka H, Yamamoto T, Oono I. Guideline for the management of hyperuricemia and gout. Gout Nucleic Acid Metab 2002, 26(suppl):1-79. [In Japanese]..
75. Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, Gerster J, Jacobs J, Leeb B, Liote F, McCarthy G, Netter P, Nuki G, Perez-Ruiz F, Pignone A, Pimentao J, Punzi L, Roddy E, Uhlig T, Zimmermann-Gorska I. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006, 65:1312-1324. 10.1136/ard.2006.055269, 1798308, 16707532.
76. Jordan KM, Cameron JS, Snaith M, Zhang W, Doherty M, Seckl J, Hingorani A, Jaques R, Nuki G. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology 2007, 46:1372-1374. 10.1093/rheumatology/kem056a, 17522099.
77. Bahn A, Hagos Y, Reuter S, Balen D, Brzica H, Krick W, Burckhardt BC, Sabolic I, Burckhardt G. Identification of a new urate and high affinity nicotinate transporter, hOAT10 (SLC22A13). J Biol Chem 2008, 283:16332-16341. 10.1074/jbc.M800737200, 18411268.
78. Van Aubel RA, Smeets PH, Heuvel JJ, Russel FG. Human organic anion transporter MRP4 (ABCC4) is an efflux pump for the purine end metabolite urate with multiple allosteric substrate binding sites. Am J Physiol Renal Physiol 2005, 288:F327-333. 10.1152/ajprenal.00133.2004, 15454390.
79. Ichida K, Hosoyamada M, Kimura H, Takeda M, Utsunomiya Y, Hosoya T, Endou H. Urate transport via human PAH transporter hOAT1 and its gene structure. Kidney Int 2003, 63:143-155. 10.1046/j.1523-1755.2003.00710.x, 12472777.
80. Bakhiya A, Bahn A, Burckhardt G, Wolff N. Human organic anion transporter 3 (hOAT3) can operate as an exchanger and mediate secretory urate flux. Cell Physiol Biochem 2003, 13:249-256. 10.1159/000074539, 14586168.
81. Gisler SM, Pribanic S, Bacic D, Forrer P, Gantenbein A, Sabourin LA, Tsuji A, Zhao ZS, Manser E, Biber J, Murer H. PDZK1: I. a major scaffolder in brush borders of proximal tubular cells. Kidney Int 2003, 64:1733-1745. 10.1046/j.1523-1755.2003.00266.x, 14531806.
82. Russel FG, Masereeuw R, van Aubel RA. Molecular aspects of renal anionic drug transport. Annu Rev Physiol 2002, 64:563-594. 10.1146/annurev.physiol.64.081501.155913, 11826280.
83. Hoque MT, Conseil G, Cole SP. Involvement of NHERF1 in apical membrane localization of MRP4 in polarized kidney cells. Biochem Biophys Res Commun 2009, 379:60-64. 10.1016/j.bbrc.2008.12.014, 19073137.